Assessment of Response to a Third Dose of the SARS-CoV-2 BNT162b2 mRNA Vaccine in Patients with Solid Tumors Undergoing Active Treatment

Yakir Rottenberg, Albert Grinshpun*, Iddo Z. Ben-Dov, Esther Oiknine Djian, Dana G. Wolf, Luna Kadouri

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

33 Scopus citations

Abstract

This cohort study evaluates the short-term humoral response to a third dose of the SARS-CoV-2 BNT162b2 vaccine in patients undergoing acute systemic therapy for solid tumors.

Original languageEnglish
Pages (from-to)300-301
Number of pages2
JournalJAMA Oncology
Volume8
Issue number2
DOIs
StatePublished - Feb 2022

Fingerprint

Dive into the research topics of 'Assessment of Response to a Third Dose of the SARS-CoV-2 BNT162b2 mRNA Vaccine in Patients with Solid Tumors Undergoing Active Treatment'. Together they form a unique fingerprint.

Cite this